Compare NICE Ltd (NICE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Repligen Corporation Common Stock — how do they compare? NICE Ltd trades at $110.41 (market cap $6.90B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 16 Days and Repligen Corporation Common Stock for 0 Days on average.
| NICE | RGEN | |
|---|---|---|
Market Cap | $6.90B | $11.14B |
Volume | 665,954 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $136.90 | $194.57 |
52-Week Low | $83.15 | $102.87 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $6.63B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $114.95, down 0.08% on the day, with a bullish technical signal from moving averages and key support at $113. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding the $2.63 estimate. Revenue reached $2.95 billion in 2025, though net income is projected to decline to $425 million in 2026. Analyst consensus is a Buy with a $124.20 price target, and recent news highlights leadership in AI-driven contact center platforms.
The outlook for NICE is positive, driven by AI revenue growth and a low valuation, but investors face risks from margin compression due to heavy AI investments and competitive pressures. The stock's current price offers a potential 8% upside to the consensus target, supported by institutional buying interest and solid cash flow generation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
